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Highlights 
 
 This case series demonstrates feasibility and safety of serial ketamine infusions (3 times 
weekly over two weeks) in addition to treatment as usual for inpatients admitted to a 
tertiary care hospital for major depressive disorder and suicidal ideation 
 All five subjects in this case series experienced benefit. 
 Scale for Suicidal Ideation scores diminished by 84% from 14.04.5 at baseline to 
2.22.5 at study endpoint (42 days) while Montgomery-Åsberg Depression Rating Scale 
scores diminished by 47% from 42.25.3 at baseline to 22.48.0.   
 There were no serious adverse events although one of five subjects dropped out due to 
the dissociative effects of ketamine. 
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Abstract 
Background: Ketamine is known to rapidly reduce depressive symptoms and suicidal ideation 
(SI) in patients with major depressive disorder (MDD), but evidence is limited for its 
acceptability and effectiveness in “real-world” settings.  This case series examines serial 
ketamine infusions in reducing SI and depression scores in adults with MDD admitted to a 
tertiary care hospital. 
Methods: Five inpatients with MDD and SI admitted to hospital in Toronto, Canada received six 
infusions of 0.5 mg/kg intravenous (IV) ketamine (n=5) over approximately 12 days, in addition 
to treatment-as-usual.  Suicide and depression rating scores (Scale for Suicidal Ideation, SSI; 
Montgomery-Åsberg Depression Rating Scale, MADRS) were obtained at baseline, on treatment 
days, on days 14 and 42 (primary endpoint). 
Results: All patients experienced benefit with ketamine.  SSI scores diminished by 84% from 
14.04.5 at baseline to 2.22.5 at study endpoint.  MADRS scores diminished by 47% from 
42.25.3 at baseline to 22.48.0.  Two patients withdrew from the study, one to initiate 
electroconvulsive therapy and one due to an adverse event (dissociative effects) during the 
ketamine infusion.   
Limitations: The major limitation of this study is the small sample size. 
Discussion: These preliminary pilot data are promising with a greater than two-fold reduction in 
SI following ketamine infusions.  They demonstrate that six serial ketamine infusions may be 
safe and feasible.  These findings support the need for large scale randomized controlled trials to 
confirm the efficacy of serial ketamine for treatment of SI in “real-world” settings. 
Keywords: major depressive disorder; suicide; ketamine; midazolam; inpatients 
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Introduction 
There is a growing body of evidence demonstrating that intravenous ketamine infusions 
can provide rapid relief of depressive symptoms in people suffering from treatment-resistant 
major depressive disorder (MDD) as well as bipolar depression with various studies showing 
rapid response to a single infusion which persists for at least 72 hours (Aan Het Rot et al. 2012; 
DiazGranados et al. 2010; George et al. 2017; Ibrahim et al. 2011; Mathew et al. 2012; 
Murrough et al. 2013a; Singh et al. 2016; Su et al. 2017; Zarate et al. 2006, 2012).  A recent 
consensus statement by the American Psychiatric Association Council of Research Task Force 
on Novel Biomarkers and Treatments states that ketamine infusion treatment may be considered 
for certain patients with MDD depending on severity, treatment-resistance and urgency 
(Sanacora et al. 2017).
 
 Similar conclusions have been drawn in the United Kingdom (Singh et al. 
2017).  Collectively, the literature indicates that ketamine infusions may be one of the most 
effective and rapid treatments for depression available, although optimism about these results 
must be tempered by the fact that the duration of response in single infusion studies with 
ketamine is often short-lived.  Emerging evidence suggests that treatment response may be 
extended with repeated infusions (Singh et al. 2016; Murrough et al. 2013b).  An open-label 
study of up to six ketamine infusions over 12 days and a follow-up period lasting up to 83 days 
thereafter found a 71% response rate in subjects with treatment resistant depression with median 
time to relapse being 18 days (Murrough et al. 2013b).   A double-blind study of twice and three-
times weekly ketamine infusions for up to four weeks with the possibility of two additional 
weeks of open-label treatment and a further three weeks of ketamine-free follow-up found that 
ketamine was superior to placebo in reducing depression scores at day 15 (Singh et al. 2016).  In 
this second study, gains in the ketamine group appeared to persist throughout the double-blind 
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phase and continued, albeit with partial regression of depression scores, through the open-label 
and ketamine-free phases of the trial (Singh et al., 2016).  While these results show some 
promise, they also indicate that even repeated administration of ketamine infusions may not 
sustain initial gains.
  
 
Single ketamine infusions have also been shown to rapidly and dramatically reduce 
suicidal ideation (SI) in depressed patients (Bartoli et al. 2017; DiazGranados et al. 2010; 
Grunebaum et al. 2017; Ionescu et al. 2016; Murrough et al. 2015; Price et al. 2009; Vulser et al., 
2018) with some evidence suggesting that this effect may be partially distinct from ketamine’s 
impact on depressive symptoms (Ballard et al. 2014; Wilkinson et al. 2017).  While this result is 
promising, there has been some concern that the rapid relief of depression or SI may be followed 
by a relapse of symptoms (Singh et al. 2017)
  
with at least one case report describing the 
culmination of such a scenario in a suicide attempt (Grunebaum et al. 2017; López-Díaz et al. 
2017; Vande Voort et al. 2016). 
While most studies of ketamine have used single doses, had short follow-up periods, and 
focused on treatment-resistant MDD samples, ketamine has also been proposed as an adjunct to 
expedite response to standard antidepressant drugs in patients who are severely depressed but not 
necessarily treatment-resistant (Hu et al. 2016).   
It follows that the most likely practical use of ketamine is as an adjunct to standard 
antidepressant treatment to rapidly relieve SI in depressed patients when time is of the essence 
such as during an acute care hospitalization.  However, despite the growing body of literature 
described above, there are few published reports of its use under “real-world” conditions, for 
example, a busy, tertiary care hospital.  One feasibility study did examine serial ketamine 
infusions for depressed patients with suicidal ideation (Vande Voort et al. 2016), however the 
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treatment was open-label and single-arm (i.e. did not include a placebo comparator group).  The 
data presented here emerge from a planned single-site, randomized, double-blind, midazolam-
controlled pilot trial which had to be terminated early due to unexpected costs associated with 
regulatory changes and increased monitoring requirements in Canada.  The study involves six 
serial ketamine infusions over approximately two weeks in reducing SI in subjects with MDD 
who were admitted to hospital for a major depressive episode.  The original hypothesis of this 
study was that ketamine would be superior to midazolam in producing improvement in suicide 
and depression scores at two endpoints (14 and 42 days).  While sample size constraints prevent 
useful between-group comparisons and limit generalizability of findings, case series data in 
subjects receiving the ketamine intervention can nevertheless be informative and may provide 
preliminary data to guide the design of future randomized controlled trials (RCTs).  The pilot 
data presented here begin to address the research gap on the effectiveness of serial ketamine 
infusions together with standard care for inpatients in a real-world setting.  
 
Methods 
Study Design and Participants 
A single-site, double-blind, pilot RCT was planned to compare approximately 12 days of 
serial infusions of ketamine vs. midazolam (placebo) as an adjunct to treatment as usual with 13 
adult inpatients with MDD and SI per group.  However, the study terminated early due to 
unexpected costs associated with regulatory changes in Canada.  The final sample included 9 
patients with 5 randomized to ketamine and 4 randomized to midazolam. 
The study was conducted at Sunnybrook Health Sciences Centre, a large university-
affiliated academic hospital in Toronto, Canada (see Figure 1 for details of recruitment).  
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Inclusion criteria were intentionally broad to mimic what would likely be used in a tertiary care 
clinical setting.  These included: 1) age 18-65 years; 2) inpatient status at entry; 3) diagnosis of 
MDD and current major depressive episode confirmed by the MINI Interview (Sheehan et al. 
1998); 4) SI at baseline as defined by a score of >0 on either of the Scale of Suicidal Ideation 
(SSI, clinician administered; Beck et al., 1979) and the Columbia-Suicide Severity Rating Scale 
(CSSRS) or both; 5) able to provide informed consent.  MDD did not have to be treatment-
resistant (defined as ≥2 failed lifetime antidepressant trials of adequate dose and duration).  
There was no minimum required depression score for entry although depression had to be severe 
enough to prompt admission to hospital.  Comorbid psychiatric conditions were identified via the 
MINI and review of clinical notes and were confirmed by clinical assessment of the trial 
investigator (MS).   
Exclusion criteria included: 1) current or past manic symptoms; 2) current or past 
psychotic symptoms; 3) current substance or alcohol dependence or substance abuse within the 
past month; 4) pervasive developmental disorder or dementia; 5) unstable medical illness (as was 
judged by the trial investigator in consultation with the anesthesia team, and based on results of a 
physical examination, vital signs, routine bloodwork and electrocardiogram; 6) medical 
condition that would contraindicate the use of ketamine/midazolam or affect their metabolism; 7) 
current treatment with ketamine; 8) any treatment that might contraindicate the use of study 
medications (e.g., concomitant monoamine oxidase inhibitors); 9) concomitant electroconvulsive 
therapy; and 10) pregnancy. 
In keeping with the notion of studying ketamine as an adjunct to standard/“real-world” 
inpatient care, study infusions were given as an add-on to treatment as usual (TAU), with subject 
medications initiated or changed at clinicians’ discretion.  There were few restrictions on what 
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TAU could entail except for concurrent ketamine or ECT.  Subjects were only required to be 
inpatients during the first infusion.  Subjects could be discharged and return to receive 
subsequent infusions at the discretion of their inpatient psychiatrist. 
Participants were randomized in 1:1 fashion to receive either 0.5 mg/kg of ketamine or 
0.045 mg/kg of midazolam, consistent with previous ketamine RCTs (Murrough et al. 2013a), in 
100 ml normal saline infused over 40 minutes.  Ketamine or midazolam was delivered on six 
separate occasions over approximately 12 days.  Infusions could be slowed to 50 minutes at the 
discretion of the anaesthesia care provider, if subjects were experiencing side effects.  Infusions 
were administered three times weekly on available treatment days until subjects had received six 
infusions.  Vital signs including heart rate, respiratory rate, blood pressure, ECG and arterial 
oxygen saturation were monitored throughout infusions and for at least one hour post-infusion.  
Anesthesiologists were present for the infusions of the earliest enrolled subjects and an 
anesthesia assistant (a professional who is trained to administer anesthetic drugs under the direct 
supervision of a physician anesthesiologist) was present to monitor all infusions thereafter.  An 
anesthesiologist was immediately available to provide support, if necessary.  Following the 
initial infusions, in-person anesthetist support was never requested and phone support was only 
sought in a single instance.   
 
Visits and Measures 
Study visits occurred at baseline, on each infusion day (visits 1-6), on days 14 (i.e. 1-3 
days after the end of acute treatment) and 42 (i.e. one month after the end of acute treatment).  
Subjects were assessed at baseline and at subsequent visits by the study investigator and a 
research coordinator both of whom were blinded to treatment allocation.  Assessment of the 
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primary hypothesis that ketamine would be superior to midazolam in reducing SI at days 14 and 
42 was done via change in SSI and the CSSRS from baseline.  The Scale of Suicidal Ideation 
(SSI) (Beck et al. 1979) is a 19-item scale that has been the historical gold standard for 
measuring suicidal ideation.  The Columbia-Suicide Severity Rating Scale (CSSRS) is the new 
gold standard for evaluating suicide risk in RCTs and involves a comprehensive set of questions 
designed for both baseline and subsequent visits (Posner et al. 2011).  The SSI was used as it 
provides a continuous measure of suicidal ideation, plans and intent while the CSSRS was used 
to capture additional categorical information including recent suicide attempts and self-harm.  
Secondary measures included the Montgomery-Åsberg Depression Rating Scale 
(MADRS), Hamilton Rating Scale for Depression (HRSD; 17-items), Clinical Global Impression 
of Severity/Improvement scales (CGI-S, CGI-I), Sheehan Disability Scale (SDS), Quick 
Inventory of Depressive Symptomatology-Self Report (QIDS-SR), and presence of adverse 
effect as reported by subjects or on inpatient clinical record.  The MADRS is a clinician 
administered depression questionnaire composed of 10 items and uses a 6-point rating scale.  It is 
the standard scale used in recent RCTs for depression (Montgomery et al. 1979).  Changes from 
baseline to endpoint on MADRS item 10 which examines suicidal thoughts were reportedly 
separately in addition to total MADRS scores.  The HRSD is a widely used clinician 
administered measure for assessing depression severity as it considers both physical and 
psychological aspects of depression (Hamilton, 1960).  The 17-item HRSD is commonly used in 
RCTs to assess treatment efficacy/effectiveness.  The CGI-S and CGI-I are designed to briefly 
assess and track severity of illness and response to treatment (Busner et al. 2007).  The SDS is a 
complementary scale to the CGI that measures functional impairment rather than severity or 
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improvement (Sheehan, 1983).  The QIDS-SR is a 16-item patient self-report scale modeled after 
diagnostic symptom criteria for MDD (Trivedi et al. 2004). 
The study was approved by the Sunnybrook Health Sciences Centre Research Ethics 
Board (ID# 361-2013), written informed consent was obtained, and the study was registered at 
ClinicalTrials.gov (NCT02593643; https://clinicaltrials.gov/ct2/show/NCT02593643). 
 Because of the small sample size, outcome data are presented descriptively for both 
subjects receiving ketamine and midazolam.  Study results use a last observation carried forward 
(LOCF) approach for those in the intent-to-treat (ITT) population, defined as any subject who 
received at least one infusion/had one post-baseline measure.  The Mann-Whitney U Test and χ2 
tests were used for baseline between-group comparisons of continuous and categorical variables 
respectively using IBM SPSS Statistics 24 (SPSS Inc, Chicago, IL) due to non-normally 
distributed data.     
 
Results 
Ketamine Case Series 
 Baseline demographics, measures and comorbidities are shown in Table 1.  Two male 
and three female subjects aged 36.87.5 yrs all of whom had treatment resistent depression 
received serial ketamine infusions.  All subjects experienced a reduction in SSI and MADRS 
scores with ketamine (Figure 2).  SSI scores for the group diminished by 84% from 14.04.5 at 
baseline to 2.22.5 at study endpoint.  MADRS scores in the ketamine group diminished by 47% 
from 42.25.3 at baseline to 22.48.0.  Mean score on MADRS item 10 (suicidal ideation) 
diminished by 68% from 3.8±0.45 at baseline to 1.2±0.84 at study endpoint.  Mean total 
MADRS scores after infusions 1-6 were 24.414.4, 21.212.7, 21.413.8, 23.612.4, 22.413.1, 
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and 22.413.3 respectively.  Two subjects withdrew from the study, one to initiate 
electroconvulsive therapy and one due to an adverse event (dissociative effects) during the 
infusion.  Two of three completers correctly guessed that they had received ketamine at study 
endpoint. 
In terms of conventional antidepressant drug treatment, two subjects were started on a 
new antidepressant during their admission/concurrent with the trial.  One subject had an 
antidepressant dose increase.  One subject continued previously prescribed antidepressants while 
one subject was on no medication throughout.  One subject received lurasidone, one subject 
received lisdexamfetamine and one subject received temazepam.  Of the three subjects who 
received all six infusions, two were hospitalized throughout and received standard treatment 
while one was discharged prior to receiving all infusions and returned as an outpatient to 
complete them. 
All subjects reported at least one non-serious adverse event.  These included dissociation, 
headache and dry skin/mouth/lips (each reported by two subjects) and diarrhea, constipation, 
chest pain, dizziness on standing, emotional detachment, drowsiness, insomnia, difficulty 
concentrating, pain/numbness at site of IV/saline lock, metallic taste, general pain and a feeling 
of being “high” or intoxicated (each reported by one subject).  Two subjects experienced 
hypertension (systolic BP >140 mmHg and/or diastolic BP >100 mmHg) during and after some 
infusions.  
 
Midazolam Case Series 
Baseline demographics, measures and comorbidities for four subjects receiving 
midazolam, two of whom were treatment-resistant, are also shown in Table 1 and SSI/MADRS 
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scores in Figure 3.  SSI scores for the group diminished by 37% from 19.89.5 to 12.515.0 at 
study endpoint.  MADRS scores diminished by 34% from 31.09.0 to 20.515.7.  Mean score on 
MADRS 10 (suicidal ideation) diminished by 29% from 3.5±1.7 at baseline to 2.5±3.0 at study 
endpoint.  Mean total MADRS scores after infusions 1-6 were 22.015.9, 12.510.0, 11.58.3, 
17.513.1, 18.38.8, and 15.513.6 respectively.  There were no dropouts in the midazolam 
group.  Three of the four completers correctly guessed that they had received midazolam at study 
endpoint.   
There was one serious adverse event, a non-fatal suicide attempt, which occurred in a 
subject receiving midazolam.   One subject was started on a new antidepressant during their 
admission/concurrent with the trial.  One subject had an antidepressant dose increase.  Two 
subjects continued previously prescribed antidepressants.  One subject received liothyronine and 
one subject received lorazepam.  Three of four subjects reported at least one non-serious adverse 
event including nausea/vomiting, headache and dizziness on standing (each reported by two 
subjects) and chest pain, dissociation, fatigue, drowsiness, sound sensitivity, strange (vivid and 
unpleasant) dreams, visual disturbances, shaking and worsening of an eating disorder (each 
reported by one subject).   
 
Discussion 
 This case series presents data indicating that six serial ketamine infusions may be safe 
and feasible and, thus, may be an acceptable adjunct to standard antidepressant therapies under 
“real-world” conditions for rapid relief of SI in patients admitted to hospital with MDD.  This 
study begins to address an important gap in the research literature which has, as yet, focused on 
efficacy rather than pragmatic designs.  Although the small sample size limits firm conclusions, 
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it is evident that, while subjects in both the ketamine and midazolam groups experienced a rapid 
reduction in SI, the reduction in the ketamine group appeared to be somewhat larger, more 
robust, and longer-lasting (up to 42 days) with SSI scores increasing in the midazolam group 
after the second infusion.  While the sample size is a limitation, the endpoint measure at 42 days 
is an important strength of the study as most previous research has focused on much shorter 
timescales.  These findings support a growing literature indicating that ketamine infusions can be 
an effective treatment for SI (Ballard et al. 2014; Bartoli et al. 2017; DiazGranados et al. 2010; 
Grunebaum et al. 2017; Ionescu et al. 2016; Murrough et al. 2015; Price et al. 2009; Wilkinson et 
al. 2017).  The greater improvement in SI scores compared to depression scores is compatible 
with the hypothesis that ketamine may have anti-suicidal effects above and beyond the effect on 
depression (Wilkinson et al. 2017).  Furthermore, although the trial did not require subjects to 
have treatment-resistant depression, all ketamine subjects and seven of nine total subjects had 
demonstrated treatment resistance.  This has two important implications.  First, it is notable that 
ketamine appeared to outperform midazolam in spite of the fact that it was delivered to a more 
treatment-resistant sample.  Second, and perhaps more importantly, it suggests that most subjects 
eligible and willing to receive ketamine in a real world, tertiary care setting may have treatment-
resistance, a finding that supports the generalizability of the existing literature focusing 
exclusively on this population. 
Given the relative novelty of ketamine for treatment for suicidality and the complex 
ethical issues surrounding an emerging treatment (Singh et al. 2017),
 
the question of how to 
position ketamine as a treatment in MDD and SI remains open to debate.  Most previous studies 
of ketamine infusions for mental disorders have focused on treatment-resistant depression (Aan 
Het Rot et al. 2012; DiazGranados et al. 2010; George et al. 2017; Ibrahim et al. 2011; Mathew 
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et al. 2012; Singh et al. 2016; Su et al. 2017; Zarate Jr et al. 2006, 2012; Murrough et al. 2013b).  
One could argue that this is inherently problematic since ketamine response is often short-lived 
and may not address the need for a long-term effective treatment in this population.  In contrast, 
given that suicidal crises are often fleeting (Daigle et al. 2005), typically subside after response 
to standard antidepressants, and the fact that antidepressant response usually occurs after several 
weeks (Undurraga et al. 2012), a treatment that rapidly alleviates SI during the waiting period for 
standard treatment to take effect is clinically meaningful.  The fact that ketamine infusion 
appears to be effective for reducing SI is especially important given the dearth of effective 
biological treatments that specifically targets suicidal ideation and behaviors (Mann et al. 2005a, 
2005b; Zalsman et al. 2016).  Although the sample size is too low to draw conclusions about 
suicidal behavior, it is noteworthy that the one suicide attempt observed occurred in the 
midazolam control group.  Larger studies are needed to corroborate this finding.  Nevertheless, 
one possible model for viewing the relationship between ketamine and standard antidepressants 
is akin to that of an analgesic given for acute fracture pain and a cast used to promote longer 
term healing.  Even if ketamine is not a panacea, this study contributes to evidence suggesting 
that it may have a place in acute care.  It is hard to overstate the potential impact of giving 
severely ill, suicidal patients hope that relief may be available in the moment. 
 This study has several limitations.  The most important limitation is the small sample size 
which resulted from the study’s premature terminations due to budgetary constraints that were 
incompatible with increased regulatory monitoring requirements in Canada.  Chance variations 
may have magnified or obscured ketamine’s anti-suicidal impact.  Assuming that the change and 
standard deviation in SSI scores observed here was maintained in a larger study, a sample of 30 
subjects in each group would be needed to detect a difference between ketamine and midazolam 
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infusions at day 42 assuming α=0.05 and β=0.80.  Allowing subjects to have multiple comorbid 
disorders in addition to MDD as well as treatment as usual, was pragmatic/generalizable to many 
inpatient units, however these factors also introduce the potential for confounding.  Furthermore, 
psychotropic medications were not controlled for.  While ketamine itself is a relatively 
inexpensive medication , the higher level of care required for infusions increases its costs 
substantially. Thus, expenses associated with repeated ketamine infusions are an important factor 
and need to be addressed as a part of the feasibility and cost benefit assessment for large scale 
use. Future studies will need to establish the optimal number of infusions to assess the efficacy 
of ketamine for extended depressive symptom relief by comparing the number of ketamine 
infusions within the same study.  The use of midazolam as an active-placebo comparator, the 
current standard in the literature (Murrough et al., 2013a; Murrough et al., 2013b; Murrough et 
al., 2015; Grunebaum et al., 2017; Fan et al., 2017), was important because its central nervous 
system effects, including sedation and amnestic effects, make it more difficult for subjects to 
guess whether they are receiving ketamine treatment.  Nevertheless, 5 out of 7 participants 
correctly guessed group assignment in the current study. Whether this reflected unblinding based 
on side-effect profile versus an inference based on improvement in mood symptoms is unclear. 
Given this study’s focus on the ketamine case series, the choice of adequate control is less 
relevant here but remains an important, unresolved issue for the field.  Finally, while this study 
examined changes in suicide and depression scores, it did not explore underlying mechanisms of 
improvement or improvement in specific domains of depression such as cognitive dysfunction 
which has been identified as an understudied aspect of MDD (Gonda et al., 2015).  Future 
studies of ketamine could include neuropsychological measures of executive function which 
plays a role in regulation of emotion. 
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 In conclusion, this case series provides initial support for the notion that serial ketamine 
may be an acceptable and effective treatment for rapid relief of SI in inpatients with MDD under 
“real-world” conditions.  The early termination of this study limited the sample size and thus the 
ability to arrive at definitive conclusions.  Nevertheless, our findings support the need for large, 
adequately-powered RCTs to determine both the efficacy and safety of serial ketamine infusions 
as an adjunct to usual treatment in real world settings.  
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Figure 1. Flow diagram indicating the number of patients screened, randomized, intervention 
allocation, follow-up, and data analysis. 
 
 
 
Assessed for eligibility (n= 13) 
Randomized (n= 9) 
Allocated to midazolam (n= 4) 
   Received midazolam (n= 4) 
Lost to follow-up (n= 1) 
Discontinued midazolam 
(n= 0) 
Analysed (n= 4) 
 Allocated to ketamine (n= 5) 
       Received ketamine (n= 5) 
Lost to follow-up (n= 0) 
Discontinued ketamine 
(n= 2) 
Analysed (n= 5) 
 Excluded (n= 4) 
   Not meeting inclusion criteria 
(n = 4) 
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Figure 2. Scale of Suicidal Ideation (A) and Montgomery–Åsberg Depression Rating Scale (B) 
Scores at Baseline, after the First Infusion, at Day 14 and 42 in Subjects Receiving Ketamine 
(K1-5). 
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Figure 3. Scale of Suicidal Ideation (A) and Montgomery–Åsberg Depression Rating Scale (B) 
Scores at Baseline, after the First Infusion, at Day 14 and 42 in Subjects Receiving Midazolam 
(M1-4).
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Table 1. Baseline demographic characteristics, measures, comorbid mental disorders and history 
of suicidal behaviour/self-harm for the nine study subjects. 
 Total sample 
(n = 9) 
Ketamine 
(n = 5) 
Midazolam 
(n = 4) 
Statistic p value 
Age (years) 32.78 ± 7.48 36.80 ± 7.46 27.75 ± 3.77 U = 2.00  0.048* 
Female 5 (56%) 3 (60%) 2 (50%) χ
2
 = 0.09 0.800 
MADRS 37.22 ± 8.90 42.20 ± 5.26 31.00 ± 9.02 U = 2.00 0.05 
HAM-D  28.67 ± 4.36 30.40 ± 3.78 26.50 ± 4.51 U = 5.50 0.266 
Treatment Resistant 
Depression† 
7 (78%) 5 (100%) 2 (50%) χ2 = 3.21 0.07 
SSI  16.56 ± 7.26 14.00 ± 4.47 19.75 ± 9.46 U = 5.50 0.268 
CGI-S  5.44 ±  0.53 5.40 ± 0.55 5.50 ± 0.58 U = 9.00 0.777 
QIDS-SR  26.56 ± 4.95 25.00 ± 4.47 28.50 ± 5.45 U = 5.00 0.221 
SDS  26.78 ± 2.68 28.40 ± 1.67 24.75 ± 2.36 U = 2.00 0.044* 
SDS Days Lost Past Week  5.67 ± 1.94 6.40 ± 0.89 4.75 ± 2.63 U = 7.00 0.421 
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SDS Days Unproductive 
Past Week  
6.44 ± 1.67 7.00 ± 0.00 5.75 ± 2.50 U = 7.50 0.264 
 
Comorbidities 
     
Anxiety Disorders 
GAD 
Social Phobia 
Panic Disorder 
Agoraphobia 
 
5 (56%) 
4 (44%) 
1 (11%) 
1 (11%) 
 
3 (60%) 
2 (40%) 
1 (20%) 
0 
 
2 (50%) 
2 (50%) 
0 
1 (25%) 
  
OCD 1 (20%) 1 (20%) 0   
PTSD 3 (33%) 2 (40%) 
 
1 (25%)   
Substance Abuse (Past) 2 (22%) 1 (20%) 1 (25%)   
BPD 2 (22%) 0 2 (50%)   
Self-harm without suicidal 
intent** 
6 (67%) 3 (60%) 3 (75%)   
Suicide attempt** 7 (78%) 3 (60%) 4 (100%)   
*p<0.05; Values indicate mean ± SD or count (%). 
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** prior to study enrollment 
†Defined as ≥2 failed antidepressant trials of adequate dose and duration. 
MADRS, Montgomery–Åsberg Depression Rating Scale; HAM-D, The Hamilton Depression 
Rating Scale; SSI, Scale of Suicidal Ideation; CGI-S, The Clinical Global Impression – Severity 
scale; QIDS-SR, Quick Inventory of Depressive Symptomatology-Self Report. ; MDD, major 
depressive disorder; GAD, generalized anxiety disorder; OCD, obsessive-compulsive disorder; 
PTSD, post-traumatic stress disorder; BPD, Borderline Personality Disorder; χ2, Chi-Squared; U, 
Mann-Whitney U Test. 
